A new generation of retinoid drugs for the treatment of dermatological diseases

Bibliography

• GOTTARDIS MM, BISCHOFF ED, SHIRLEY MA, et al.: Chemoprevention of mammary carci-noma by LGD1069 (TargretinTm): an RXR-selective ligand. Cancer Res. (1997) 56:5566–5570.
   Web of Science ®Google Scholar
• STANDEVEN AM, BEARD RL, JOHNSON AT, et al.: Retinoid-induced hyperglyceridemia in rats is mediated by retinoic acid receptors. Fund. AppL Tox. (1996) 33:254-271. Demonstration of RAR-mediated hyperglyceridaemia.
   Google Scholar
• KISTLER A, TSUCHIYA T, TSUCHIYA M, KLAUS M: Teratogenicity of arotinoids (retinoids) in vivo and in vitro. Arch. Toxicol. (1990) 64:616–622.
   PubMed Web of Science ®Google Scholar
• SHALITA AR: Lipid and teratogenic effects of retinoids. J. Am. Acad. Dermatol. (1988) 19:197–198.
   PubMed Web of Science ®Google Scholar
• HEYMAN RA, MANGELSDORF DJ, DYCK JA, et al.: 9-cis retinoic acid as a high affinity ligand for retinoid X receptors. Cell (1992) 68:397-406. Demonstration of 9-cis RA as a ligand for RXRs.
   PubMedGoogle Scholar
• LEVIN AA, STURZENBECKER LJ, KAZMAR S, et al.: 9-cis retinoic acid stereoisomer binds and activates the nuclear receptor RXRa. Nature (1992) 355:359-361. Demonstration of 9-cis RA as a ligand for RXRs.
   PubMedGoogle Scholar
• MANGELSDORF DJ, UMESONO K, EVANS RM: The retinoid receptor. In: The Retinoids. Academic Press, Orlando, Florida (1994):319-349.A comprehensive review of the field up to 1992.
   Google Scholar
• LEID M, KASTNER P, CHAMBON P: Multiplicity generates diversity in the retinoic acid signaling pathways. Trends Biochem. Sci. (1992) 17:427–433.
   PubMed Web of Science ®Google Scholar
• VERSCHOORE M, BOUCHER M, CZERNIELEWSKI J, HENSBY C: Topical retinoids: their uses in dermatology. Dermatol. Clin. (1993) 11:107–115.
   PubMed Web of Science ®Google Scholar
• Sporn MB, Roberts All, Goodman DS (Eds.), Raven Press Ltd, New York (1994):631–658.
   Google Scholar
• A comprehensive review of the field up to 1992.
   Google Scholar
• Sporn MB, Roberts AB, Goodman DS (Eds.), Raven Press Ltd., New York (1994):597-630.A comprehensive review of the field up to 1993.
   Google Scholar
• ORFANOS CE, EHLERT R, GOLLNICK H: The retinoids. A review of their clinical pharmacology and therapeutic use. Drugs (1987) 34:459–503.
   PubMed Web of Science ®Google Scholar
• SMITH MA, PARKINSON DR, CHESON BD, FRIEDMAN MA: Retinoids in cancer therapy. J. Clin. Oncol. (1992) 10:839–864.
   PubMed Web of Science ®Google Scholar
• VOKES EE, WEICHSELBAUM RR, LIPPMAN SM, HONG WK: Head and neck cancer. New Engl. J. Med. (1993) 328:184–194.
   PubMed Web of Science ®Google Scholar
• LIPPMAN SM, KESSLER JF, MEYSKENS FL, Jr.: Retinoids as preventive and therapeutic anticancer agents (Part I). Cancer Treatment Reports (1987) 71:391–405.
   PubMedGoogle Scholar
• SAURAT JH: Retinoids in dermatology. Rev. Prat. (1992) 42:69–75.
   PubMedGoogle Scholar
• MUKHTAR H, MERCURIO MG, AGARWAL R: Murine skin carcinogenesis: relevance to humans. In: Skin Cancer: Mechanisms and Human Relevance. CRC Press (1995):3–8.
   Google Scholar
• FROST, SULLIVAN: US Prescription Dermatology Pharmaceuticals Markets. Publication #5352–52.
   Google Scholar
• MILLS CM, MARKS R: Adverse reactions to oral retinoids. An update. Drug Saf (1993)9:280–290.
   PubMed Web of Science ®Google Scholar
• DAVID M, HODAK E, LOWE NJ: Adverse effects of retinoids. Med. Toxicol. Adverse Drug Exp. (1988) 3:273–288.
   PubMedGoogle Scholar
• YOB EH, POCHI PE: Side-effects and long-term toxicity of synthetic retinoids. Arch. Dermatol. (1987) 123:1375–1378.
   PubMed Web of Science ®Google Scholar
• WARRELL RP: Retinoid resistance in acute promyelocytic leukemia: new mechanisms, strategies and implications. Blood (1993) 82:1949–1953.
   PubMed Web of Science ®Google Scholar
• LIPPMAN SM, MEYSKENS FL, Jr.: Treatment of advanced squamous cell carcinoma of the skin with isotretinoin. Ann. Intern. Med. (1987) 107:499–501.
   PubMed Web of Science ®Google Scholar
• LIPPMAN S, PARKINSON DR, ITRI LM, et al.: 13-cis-retinoic acid and interferon-alpha-2a. Effective combination therapy for advanced squamous cell carcinoma of the skin. J. Natl. Cancer Inst. (1992) 84:235–240.
   PubMed Web of Science ®Google Scholar
• Clinical efficacy of retinoid and INF-a combination therapy in SCC.
   Google Scholar
• BENEDETTI F, MILLER WH, RIGAS J, et al.: Initial clinical and pharmacokinetic study of 9-cis retinoic acid. Proceedings of the American Association for Cancer Research (1995) 36:1445.
   Google Scholar
• MILLER WH, JAKUBOWSKI A, TONG WP, et al.: 9-cis retinoic acid reduces complete remission but does not reverse clinically acquired retinoid resistance in acute promyelocytic leukemia. Blood (1995) 55:3021–3027.
   Google Scholar
• MILLER VA, BENEDETTI FM, RIGAS JR, et al.: Initial clinical study of a retinoid X receptor (RXR) agonist. Proceedings of the American Association for Cancer Research (1995) 36:1445.
   Google Scholar
• FENAUX P, CASTAIGNE S, DOMBERT H, et al.: All-trans retinoic acid followed by intensive chemotherapy gives a high complete remission rate and may prolong remissions in newly diagnosed acute promyelocytic leukemia: a pilot study on 26 cases. Blood (1992) 80:2176–2181.
   PubMed Web of Science ®Google Scholar
• FENAUX P, CHASTANG C, CHOMIENNE C, DEGOS L: Tretinoin with chemotherapy in newly diagnosed acute promyelocytic leukemia. Lancet (1994) 343:1033.
   PubMed Web of Science ®Google Scholar
• YU VC, DELSERT C, ANDERSON B, et al.: RXR-13: a co-regulator that enhances binding of retinoic acid, thyroid hormone and vitamin D receptors to their cognate response elements. Cell (1991) 67:1251–1266.
   PubMed Web of Science ®Google Scholar
• KLIEWER SA, UMESONO K, MANGELSDORF DJ, EVANS RM: Retinoid X receptor interacts with nuclear receptors in retinoic acid, thyroid hormone and vitamin D3 signaling. Nature (1992) 355:446–449.
   PubMed Web of Science ®Google Scholar
• Demonstration of heterodimerisation of RXR with RAR, TR and VDR.
   Google Scholar
• MARKS MS, HALLENBECK PL, NAGATA T, et al.: H-2RHBP (RXRI3) heterodimerization provides a mechanism for combinatorial diversity in the regulation of retinoic acid and thyroid responsive genes. EMBO 1 (1992) 11:1419–1435.
   Google Scholar
• BUGGE TH, POHL J, LONNOY 0, STUNNENBERG HG: RXRoc, a promiscuous partner of retinoic acid and thyroid hormone receptors. EMBO 1 (1992) 11:1409–1418.
   Google Scholar
• LEID M, KASTNER P, LYONS R, et al.: Purification, cloning, and RXR identity of the HeLa cell factor with which RAR or TR heterodimerizes to bind target sequences efficiently. Cell (1992) 68:377–395.
   PubMed Web of Science ®Google Scholar
• RXR heterodimerises with RAR and TR.
   Google Scholar
• MANGELSDORF DJ, ONG ES, DYCK JA, EVANS RM: A nuclear receptor that identifies a novel retinoic acid response pathway. Nature (1990) 345:224–229.
   PubMed Web of Science ®Google Scholar
• KLIEWER SA, UMESONO K, NOONAN DJ, HEYMAN RA, EVANS RM: Convergence of 9-cis-retinoic acid and peroxisome proliferator signaling pathways through heterodimer forma-tion of their receptors. Nature (1992) 358:771–774.
   PubMed Web of Science ®Google Scholar
• ISSEMANN I, GREEN S: Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature (1990) 347:646–650.
   Google Scholar
• GOTTLICHER M, WIDMARK E, LI Q, GUSTAFSSON JA: Fatty acids activate a chimera of the dofibric acid activated receptor and the glucocorticoid receptor. Proc. Natl. Acad. Sci. USA (1992) 89:4653–4657.
   PubMed Web of Science ®Google Scholar
• IBRAHIMI A, TEBOUL L, GAILLARD D, et al.: Evidence for a common mechanism of action for fatty acids and thiazolidinedione antidiabetic agents on gene expression in preadipose cells. Mol. Pharmacol. (1994) 46:1070–1076.
   PubMed Web of Science ®Google Scholar
• KUROKAWA R, YU V, NAAR A, et al.: Differential orientations of the DNA binding domain and carboxy-terminal dimerization interface regulate binding site selection by nuclear receptor heterodimers. Genes Dev. (1993) 7:1423–1435.
   PubMed Web of Science ®Google Scholar
• KUROKAWA R, DIRENZO J, BOEHM M, et al.: Regulation of retinoid signaling by receptor polarity and allosteric control of ligand binding. Nature (1994) 371:528–531.
   PubMed Web of Science ®Google Scholar
• PERLMANN T, RANGARAJAN PN, UMESONO K, EVANS RM: Determinants for selective RAR and TR recognition of direct repeat HREs. Genes Dev. (1993) 7:1411–1422.
   PubMed Web of Science ®Google Scholar
• NICHOLSON RC, MADER S, NAGPAL S, et al.: Negative regulation of the rat stromelysin gene promoter by retinoic acid is mediated by an AP1 binding site. EMBO J. (1990) 9:4443-4454. RARs antagonise AP1-dependent gene expression.
   PubMedGoogle Scholar
• SHUELE R, RANGARAJAN P, YANG N, et al.: Retinoic acid is a negative regulator of AP-1 responsive genes. Proc. Natl. Acad. Sci. USA (1991) 88:6092-6096. RAR antagonism of AP1-dependent genes.
   Google Scholar
• YANG-YEN H-F, GANG X-K, GREENER G, et al.: Antagonism between retinoic acid receptors and AP-1: implications for tumor promotion and inflammation. New Biologist (1991)3:1206-1219. RAR-API antagonism.
   PubMedGoogle Scholar
• NAGPAL S, ATHANIKAR J, CHANDRARATNA RAS: Separation of transactivation and AP1 antagonism functions of retinoic acid receptor-a. J. Biol. Chem. (1995) 270:923–927.
   PubMed Web of Science ®Google Scholar
• Pharmacological separation of transactivation of API antagonism properties of RARs.
   Google Scholar
• FELLI MP, VACCA A, MECO D, et al.: Retinoic acid-induced down-regulation of the interleukin-2 promoter via cis-regulatory sequences containing an octamer motif. MoL Cell. Biol. (1991) 11:4771–4778.
   PubMed Web of Science ®Google Scholar
• ISHIDA S, SHUDO K, TAKADA S, KOIKE K: Transcription from the P2 promoter of human protooncogene myc is suppressed by retinoic acid through an interaction between the E2F element and its binding proteins. Cell Growth and Differentiation (1994) 5:287–294.
   PubMedGoogle Scholar
• CREEK KE, JENKINS GR, KHAN MA, et al.: Retinoic acid suppresses human papillomavirus type 16 (HPV16)-mediated transformation of human keratinocytes and inhibits the expression of the HPV16 oncogenes. In: Diet and Cancer: Markers, Prevention, and Treatment. Plenum Press (1994):19–35.
   Google Scholar
• BARTSCH D, HOYE B, BAUST C, ZUR HAUSEN H, SCHWARZ E: Retinoic acid-mediated repression of human papillomavirus 18 transcription and different ligand regulation of the retinoic acid receptor 13 gene in non-tumorigenic and tumorigenic HeLa hybrid cells. EMBO (1992) 11:2283–2291.
   PubMed Web of Science ®Google Scholar
• WRIGHT JK, CLARK MI, CAWSTON TE, HAZLEMAN BL: The secretion of the tissue inhibitor of metalloproteinase (TIMP) by human synovial fibroblasts is modulated by all-trans-retinoic acid. Biochim. Biophys. Acta (1991) 1133(1):25–30.
   PubMed Web of Science ®Google Scholar
• FANJUL A, DAWSON MI, HOBBS PD, et al.: A new class of retinoids with selective inhibition of AP-1 inhibits proliferation. Nature (1994) 372:107-111. Transcriptionally inert but AP1-selective retinoids inhibit cell proliferation.
   PubMedGoogle Scholar
• WEINSTEIN GD: Safety, efficacy and duration of therapeutic effect of tazarotene used in the treatment of plaque psoriasis. Br. I Dermatol. SuppL (1996) 135:32–36.
   PubMedGoogle Scholar
• BOEHM MF, ZHANG L, BADEA BA, et al.: Synthesis and structure activity relationships of novel retinoid X receptor selective retinoids. J. Med. Chem. (1994) 37:2930-2941. Describes the design and synthesis of the first RXR selective retinoid (LGD1069) to enter clinical trials.
   Google Scholar
• RIGAS JR, MILLER VA, LEVINE DM, et al.: Lipoprotein alterations in patients treated with novel retinoids. Proceedings of the American Association for Cancer Research (1995) 36:3012.
   Google Scholar
• BOEHM MF, ZHANG L, ZHI L, et al.: Design and synthesis of potent retinoid X receptor selective ligands that induce apoptosis in leukemia cells. J. Med. Chem. (1995) 38:3146–3155.
   PubMed Web of Science ®Google Scholar
• NAGY L, THOMAZY VA, SHIPLEY GL, et al.: Activation of retinoid X receptors (RXR) induces apoptosis in HL-60 cell lines. Mol. Cell. Biol. (1995) 15:3540–3551.
   PubMed Web of Science ®Google Scholar
• APFEL C, BAUER F, CRETTAZ M, et al.: A retinoic acid receptor a antagonist selectively counteracts retinoic acid effects. Proc. Natl. Acad. Sci. USA (1992) 89:7129–7133.
   PubMed Web of Science ®Google Scholar
• KANEKO S, KAGECHIKA H, KAWACHI E, HASHIMOTO Y, SHUDO K: Retinoid antagonists. Med. Chem. Res. (1991) 1:220–225.
   Google Scholar
• ECKHARDT K, SCHMITT G: A retinoic acid receptor a antagonist counteracts retinoid terato-genicity in vitro and reduced incidence and/or severity of malformations in vivo. Tox. Lett. (1994) 70:299–308.
   PubMed Web of Science ®Google Scholar
• PASATIEMPO AMG, BOWMAN TA, TAYLOR CE, ROSS AC: Vitamin A depletion and reple-tion: effects on antibody response to the capsular polysaccharide of Streptococcus pneumoniae, type Ill (SSS-III). Am. I Clin. Nutr. (1989) 49:501–510.
   PubMed Web of Science ®Google Scholar
• JAMOULLE JC, GRANDJEAN L, LAMAUD E, SHROOT B, SCHAEFER H: Follicular penetration and distribution of topically applied CD271, a new naphthoic acid derivative intended for topical acne treatment. I Invest. Dermatol. (1990) 94:731–732.
   PubMed Web of Science ®Google Scholar
• CHANDRARATNA RAS: Tazarotene - first of a new generation of receptor-selective retinoids. Br. I Dermatol. Suppl. (1996) 135:18–32.
   PubMedGoogle Scholar
• MORK NJ, KOLBENSTVEDT A, AUSTAD J: Efficacy and skeletal side-effects of two years' acitretin treatment. Acta Derm. Venereol. Stockholm (1992) 72:445–448.
   PubMed Web of Science ®Google Scholar
• Saurat JH (Ed.), Karger, Basel, New York (1991):204–213.
   Google Scholar
• KULLAVANIJAYA P, KULTHANAN K: Clinical efficacy and side-effects of Acitretin on the disorders of keratinization: a one year study. I Dermatol. (1993) 20:501–506.
   PubMedGoogle Scholar
• FUKASAWA H, IIJIMA T, KAGECHIKA H, HASHIMOTO Y, SHUDO K: Expression of the ligand binding domain-containing region of retinoic acid receptors alpha, beta and gamma in Es-cherichia coil and evaluation of ligand-binding selectivity. Biol. Pharm. Bull. (1993) 16:343–348.
   PubMed Web of Science ®Google Scholar
• MEHTA K, SADEGHI T, MCQUEEN T, LOPEZ-BERESTEIN G: Liposomal encapsulation cir-cumvents the hepatic clearance mechanisms of all-trans-retinoic acid. Leukemia Research (1994) 18:587–596.
   PubMed Web of Science ®Google Scholar
• MEHTA K, LOPEZ-BERESTEIN G, MCQUEEN T, ANDREEFF M, ESTEY E: Preclinical devel-opment of an intravenous all-trans-retinoic acid formulation: liposomal-RA. Proceedings of the American Association for Cancer Research (1995) 36:1282.
   Google Scholar
• BORIS A, HURLEY J, WONG CQ, COMAI K, SHAPIRO S: Sebum-suppressing activity of the nonpolar arotinoid Ro 15-0778 in rodents. Arch. Dermatol. Res. (1988) 280:246–251.
   PubMed Web of Science ®Google Scholar
• SHAPIRO SS, HURLEY J: Effect of retinoids on sebaceous glands. Methods Enzymol. (1990) 190:326–333.
   PubMed Web of Science ®Google Scholar
• BRINCKERHOFF CE, COFFEY JW, SULLIVAN AC: Inflammation and collagenase production in rats with adjuvant arthritis reduced with 13-cis-retinoic acid. Science (1983) 221:756–758.
   PubMed Web of Science ®Google Scholar
• KUVVABARA K, SHUDO K, IIORI Y: Novel synthetic retinoic acid inhibits rat collagen arthritis and differentially affects serum immunoglobulin subclass levels. FEBS Lett. (1996) 378:153–158.
   PubMed Web of Science ®Google Scholar
• MUKHERJEE R, DAVIES PJA, CROMBIE D, et al.: Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature (1997). In press.
   PubMedGoogle Scholar